รอบรั้วมหาวิทยาลัยราชภัฏลำปาง

EGFR ADCs (Antibody-Drug Conjugates) represent a promising therapeutic strategy in the treatment of cancers, particularly those characterized by overexpression or mutations of the Epidermal Growth Factor Receptor (EGFR). These conjugates combine the specificity of monoclonal antibodies targeting EGFR with the potent cytotoxic effects of chemotherapeutic agents.

The design of EGFR ADCs involves linking a cytotoxic drug to an antibody specific for EGFR. Upon binding to the cancer cell's EGFR, the ADC is internalized, and the cytotoxic agent is released inside the cell, leading to targeted cell death while minimizing damage to surrounding healthy tissues. This targeted approach aims to reduce the side effects commonly associated with traditional chemotherapy.

EGFR ADCs are being actively researched and developed for various types of cancer, including non-small cell lung cancer (NSCLC) and other solid tumors where EGFR plays a critical role in tumor growth and survival. Ongoing clinical trials and research are focused on improving the efficacy, safety, and therapeutic index of these innovative treatments, which hold the potential to improve outcomes for patients with EGFR-driven cancers.